1. Global Parkinson’s Disease Prevalence & Statistics
1.1 North America
1.1.1 United States
1.1.2 Canada
1.2 Europe
1.2.1 United Kingdom
1.2.2 Germany
1.2.3 Russia
1.3 Asia- Pacific
1.3.1 China
1.3.2 Japan
1.3.3 India
1.3.4 South Korea
1.3.5 Australia
1.3.6 New Zealand


2. Global Parkinson’s Drug Market Analysis
2.1 Current Market Scenario
2.2 Global Parkinson’s Drug Market Segmentation
2.2.1 Regional Segmentation
2.2.2 Segmentation by Products


3. Anti-Parkinson’s Drugs - Availability, Dosage & Price Analysis
3.1 Levodopa/Carbidopa Therapeutics
3.1.1 Duopa/Duodopa
3.1.2 Rytary
3.1.3 Sinemet
3.2 Dopamine Agonist
3.2.1 Rotigotine (Neupro)
3.2.2 Pramipexole
3.2.3 Ropinirole
3.3 MAO B Inhibitors
3.3.1 Selegiline
3.3.2 Safinamide (Xadago)
3.3.3 Rasagiline
3.4 Catechol O-methyltransferase (COMT) inhibitors
3.4.1 Entacapone
3.4.2 Tolcapone
3.5 Other Anti-Parkinson’s Drugs
3.5.1 Benztropine
3.5.2 Amantidine
3.5.3 Istradefylline (Nourianz)
3.5.4 Rivastigmine


4. Global Parkinson’s Drug Market Drivers


5. Challenges for Global Parkinson’s Drug Market


6. Global Parkinson’s Drug Market Future Outlook


7. Global Parkinson’s Disease Drug Clinical Pipeline Overview
7.1 By Phase
7.2 By Drug Class
7.3 By Mechanism of Action
7.4 By Formulation
7.5 By Country


8. Global Parkinson’s Disease Drug Clinical Trial: Research Phase
8.1 Overview
8.2 Clinical Pipeline Insight


9. Global Parkinson’s Disease Drug Clinical Trial: Preclinical Phase
9.1 Overview
9.2 Clinical Pipeline Insight



10. Global Parkinson’s Disease Drug Clinical Trial: Clinical Phase
10.1 Overview
10.2 Clinical Pipeline Insight


11. Global Parkinson’s Disease Drug Clinical Trial: Phase-I
11.1 Overview
11.2 Clinical Pipeline Insight


12. Global Parkinson’s Disease Drug Clinical Trial: Phase-I/II
12.1 Overview
12.2 Clinical Pipeline Insight


13. Global Parkinson’s Disease Drug Clinical Trial: Phase-II
13.1 Overview
13.2 Clinical Pipeline Insight


14. Global Parkinson’s Disease Drug Clinical Trial: Phase-II/III
14.1 Overview
14.2 Clinical Pipeline Insight


15. Global Parkinson’s Disease Drug Clinical Trial: Phase- III Phase
15.1 Overview
15.2 Clinical Pipeline Insight


16. Global Parkinson’s Disease Drug Clinical Trial: Preregistration Phase
16.1 Overview
16.2 Clinical Pipeline Insight


17. Global Parkinson’s Disease Drug Clinical Trial: Registered Phase
17.1 Overview
17.2 Clinical Pipeline Insight


18. Global Marketed Parkinson’s Drugs Clinical Insight


19. Competitive Landscape
19.1 Novartis
19.2 Merck
19.3 Pfizer
19.4 GlaxoSmithKline plc
19.5 Roche
19.6 Teva Pharmaceuticals
19.7 AbbVie Inc.
19.8 Mylan
19.9 Boehringer Ingelheim
19.10 Orion Pharma
19.11 ACADIA Pharmaceuticals Inc